Lataa...
CCR 20(th) Anniversary Commentary: In the Beginning, There Was PS-341
Proteasome inhibitors have a 20 year history in cancer therapy. The first proteasome inhibitor, bortezomib, a break-through multiple myeloma treatment, moved rapidly through development from bench in 1994 to first approval in 2003. CCR has chronicled development of proteasome inhibitors with publica...
Tallennettuna:
| Julkaisussa: | Clin Cancer Res |
|---|---|
| Päätekijät: | , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2015
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4349205/ https://ncbi.nlm.nih.gov/pubmed/25733705 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-2549 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|